SomaGenics Inc. Company Profile
SomaGenics is a privately held company that develops innovative RNA technologies for therapeutic and diagnostic uses. SomaGenics' lead therapeutic program, against hepatitis C virus, has successfully completed efficacy evaluations in preclinical animal models and is ready for clinical development.
News from SomaGenics Inc.:
SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
SANTA CRUZ, Calif., Nov. 12, 2012 /PRNewswire/ – SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, has been awarded US Patent No. 8,283,460 for key aspects of the company’s sshRNA therapeutic platform. sshRNAs are small synthetic stem-loop (or ha…
SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
SANTA CRUZ, Calif., July 24, 2012 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, announced the publication of a study reporting the mechanism of action of its sshRNAs, the class of molecules that forms the basis of the company’s therapeutic platfor…
SomaGenics’ sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
SANTA CRUZ, Calif., Sept. 20, 2011 — SomaGenics, Inc., a biotechnology company specializing in RNA-based technologies, presented exciting data on the efficacy of RNA interference (RNAi) therapeutics against Hepatitis C virus (HCV) based on the company’s sshRNA platform.